About ProBion

We are at the forefront in the field of probiotics and human health

  • ProBion represents quality and innovation. It is produced in Sweden by Wasa Medicals - member of International Probiotic Association - IPA.
  • “The International Probiotics Association (IPA) is an international organization with members equally divided between industry and academia and its goal is to provide a unique forum for the exchange of research and the latest breakthroughs in probiotic technology and new product development.”
  • Driven by MD. Lennart Cedgard with 35+ years of clinical experience in intestinal microecology and probiotics amongst therapists.
  • Wasa Medicals and ProBion Innovation Sweden are working together with research and development in the field of probiotics and prebiotics.
  • The company have developed a low-compression matrix technique for making tablets containing viable probiotic cultures. The method makes it possible to maintain the viability of the cultures during the formation of tablets. The cultures in the tablet are protected from oxygen and humidity during storage, which improves the viability and sustainability of the products.
  • The cultures are protected against gastric- and bile acids during the passage through the GI-tract and a regulated disintegration so called “controlled slow release” take place in the whole digestive system. Due to the disintegration profile of the tablet a large area of the small intestine and the colon are exposed to vigorous and viable bacteria. This improves the effect of the probiotic cultures.

Honest Science

Precise & Innovative

  • ProBion Innovation Sweden AB (PISA) based at Sahlgrenska Academy at University of Gothenburg, Sweden is a biotechnology research company, with the distinct objective to link and highlight the effects of probiotics on our most common disorders.
  • We perform both clinical and basic science studies looking upon the effects of probiotics on various different diseases, such as colon cancer, metabolic diseases, celiac disease, infertility and irritable bowel syndrome. We collaborate with universities, hospitals and institutions around the world. We believe that our research at ProBion Innovation Sweden AB will greatly enhance the health and quality of life for people.

Our Technology

We are at the forefront in the field of probiotics and human health

  • In order to sustain a high yield of viable probiotic bacteria in the intestine, we require that the vehicle used to introduce them in the gut is as resistant as possible to gastric juices and bile acids. In addition, employing an accurate gut navigation delivery system, carrying High Quality - High Viability probiotics loads and precise Time Triggered Targeting efficacy are paramount requirements for effective reliable results in achieving our objectives.
  • The number and amount of viable bacteria is supervised using Flow Cytometric analysis. This method is direct and enables us to better monitor the dose-response outcome. We use the innovative formulation of the ProBion Tablet Matrix to ensure these features in every step of our studies. Its sustained storage viability together with its slow-release profile is absolutely unique for the ProBion Tablet Matrix.

Meet The Board

ProBion innovation Sweden AB (PISA)

Katarina Ejeskär

Chief Research Officer

Victoria Rotter Sopasakis

Chief Executive Officere

Yvonne Wettergren

Chairman Of The Board

Charles Hanson

Board Member

Lennart Cedgård

Board Member